CIK 0000879407 · Large accelerated filer
ARROWHEAD PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ARWR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Sep 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 460408024
- Phone
- 626-696-4702
- Business address
- 177 E COLORADO BLVD, SUITE 700, PASADENA, CA, 91105
- Former names
- ARROWHEAD RESEARCH CORP, INTERACTIVE GROUP INC, INTERACTIVE INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,186,600
- in 2 filings
Net −$1,186,600. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-04 | O'Brien Patrick COO and General Counsel | Sale 10b5-1 | −1,600 | $32.63 | $52K | 402,226 |
| 2024-01-04 | O'Brien Patrick COO and General Counsel | Grant or award 10b5-1 | +85,000 | 487,226 | ||
| 2024-01-03 | Hamilton James C Chief Discovery/Trans Medicine | Sale 10b5-1 | −3,500 | $31.81 | $111K | 178,734 |
| 2024-01-03 | Hamilton James C Chief Discovery/Trans Medicine | Sale 10b5-1 | −2,300 | $32.52 | $75K | 176,434 |
| 2024-01-03 | Hamilton James C Chief Discovery/Trans Medicine | Sale 10b5-1 | −500 | $33.30 | $17K | 175,934 |
| 2024-01-03 | O'Brien Patrick COO and General Counsel | Sale 10b5-1 | −3,849 | $31.83 | $123K | 408,726 |
| 2024-01-03 | O'Brien Patrick COO and General Counsel | Sale 10b5-1 | −2,800 | $32.52 | $91K | 405,926 |
| 2024-01-03 | O'Brien Patrick COO and General Counsel | Sale 10b5-1 | −400 | $33.41 | $13K | 405,526 |
| 2024-01-03 | O'Brien Patrick COO and General Counsel | Sale 10b5-1 | −1,700 | $32.65 | $56K | 403,826 |
| 2024-01-02 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −4,634 | $30.74 | $142K | 3,720,366 |
| 2024-01-02 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −5,318 | $31.25 | $166K | 3,715,048 |
| 2023-12-20 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −12,000 | $28.54 | $342K | 3,725,000 |
| 2023-12-15 | Ferrari Mauro Director | Grant or award | +14,987 | $25.41 | $381K | 65,825 |
| 2023-12-15 | PERRY MICHAEL S Director | Grant or award | +14,987 | $25.41 | $381K | 114,754 |
| 2023-12-15 | OLUKOTUN ADEOYE Y Director | Grant or award | +14,987 | $25.41 | $381K | 22,854 |
| 2023-12-15 | Vakiener Victoria Director | Grant or award | +14,987 | $25.41 | $381K | 36,721 |
| 2023-12-15 | GIVEN DOUGLAS B Director | Grant or award | +14,987 | $25.41 | $381K | 132,622 |
| 2023-12-15 | Waddill William D. Director | Grant or award | +14,987 | $25.41 | $381K | 51,804 |
| 2023-11-20 | San Martin Javier Chief Medical Officer | Sale 10b5-1 | −14,758 | $28.73 | $424K | 136,742 |
| 2023-11-20 | San Martin Javier Chief Medical Officer | Sale 10b5-1 | −4,942 | $29.00 | $143K | 131,800 |
Page 10 of 38 · 752 trades